Skip to content

ChatGPT

Log in

You said:

Neftaly Guidelines for the management of HIV infection in pregnant women

ChatGPT said:

It appears I could not find any guidelines specifically titled “Neftaly Guidelines for the management of HIV infection in pregnant women” through available online sources. It’s possible this is an internal or less commonly referenced protocol. However, international and South African national recommendations align closely with best practices, and I compiled the most up‑to‑date guidance based on official and widely respected sources:

---

???? International Guidelines (e.g. SCIENTIFIC LITERATURE)

According to up-to-date clinical guidance (e.g., Guideline No. 450: Care of Pregnant Women Living with HIV… published in 2024): NICD+9PubMed+9sahivsoc.org+9ScienceDirect

• ART initiation: All pregnant women living with HIV should start antiretroviral therapy regardless of CD4 count/viral load.
• No dose adjustment: Routine dose adjustments during pregnancy are not recommended.
• Safety during first trimester: Pregnant women should not discontinue ART due to theoretical concerns about teratogenicity.
• Resistance testing: Viral genotyping and resistance testing is recommended before or soon after initiating treatment.
• ART regimen continuation: Established regimens (including those with efavirenz, nevirapine, or dolutegravir) are generally safe to continue; switching should be based on expert advice.
• Monitoring: Clinical, virological, and immunological monitoring every 4–12 weeks, including near delivery and postpartum assessments.
• Obstetrical ultrasound: Routine first-trimester (11–14 weeks) screening, detailed anatomy scan at 19–20 weeks, and at least one third-trimester scan as indicated.
• Mode of delivery:
  • Vaginal delivery is recommended if viral load is undetectable (< 50 copies/mL) in the 4 weeks prior to delivery and there are no obstetric indications.
  • Scheduled c‑section is advised around 38 weeks if viral load ≥ 400 copies/mL, unknown, or no ART.
• Intrapartum zidovudine (AZT): Recommended for women with detectable/inadequate viral suppression, starting at onset of labor or rupture of membranes; may be omitted for stable undetectable patients under specialist guidance.
• Infant feeding: In settings like Canada, formula feeding is standard; if breastfeeding is chosen against recommendations, enhanced infant prophylaxis and close follow-up should be offered. aidsdatahub.org+5ScienceDirect+5Wikipedia+5

---

???????? South African National Clinical Guidelines (2023/2019)

2023 Consolidated ART Guidelines:

• Adopt Option B+: lifelong ART for all pregnant and breastfeeding women regardless of CD4 or clinical stage. ojs.sabinet.co.za+3sajhivmed.org.za+3aidsdatahub.org+3
• First-line ART is Dolutegravir-based fixed-dose combination (TLD) for all eligible women — effective and safe in pregnancy.
• Virological suppression (VL ≤50 copies/mL) is essential, and VL > 50 copies/mL triggers urgent clinical action. ojs.sabinet.co.za+14sahivsoc.org+14PubMed+14

2019 PMTCT Communicable Infections Guideline:

• Started Option B+ in 2015, leading to drastic reductions in vertical transmission rates (from ~23% in 2003 to ~0.7% in 2019).
• The focus is on:
  1. Preventing unintended pregnancy and primary HIV infection among reproductive-age women;
  2. Maintaining maternal viral suppression before, during, and after pregnancy;
  3. Enhanced infant prophylaxis during the breastfeeding period if maternal suppression is inadequate. sajhivmed.org.za+1aidsdatahub.org+1

---

???? Summary Table: Key Recommendations

Phase	Key Management Points
Pre-pregnancy / Conception	Counsel women living with HIV; aim for undetectable VL for 4–6 months before conception; initiate DTG-based ART, manage comorbidities (e.g., syphilis, TB). Wikipedia+2Readkong+2ScienceDirect+2
Pregnancy	Start ART as early as possible, ideally immediately after diagnosis; do not interrupt therapy in first trimester. Monitor VL/CD4 every 4–12 weeks, perform recommended ultrasound scans.
Delivery	If VL <50 copies/mL near term → vaginal birth; if VL ≥200–400 copies/mL or unknown → schedule cesarean at 38 weeks. Add IV AZT if suppression is inadequate.
Postpartum / Breastfeeding	Continue ART; discourage breastfeeding unless supported by enhanced neonatal prophylaxis and surveillance; continue infant prophylaxis per maternal VL status.

---

???? How Does This Align with “Neftaly”?

If “Neftaly Guidelines” refers to protocols followed in South African or other resource‑limited settings, they would closely mirror these national and international recommendations:

• Universal lifelong ART for pregnant women (Option B+).
• Early initiation, regular VL monitoring, and support with adherence.
• Delivery planning based on VL for delivery mode and intrapartum AZT use.
• Integration of obstetric, HIV, and postnatal care to support maternal and infant health.
• Infant prophylaxis tailored to maternal viral suppression status.

---

✅ Final Notes

• These guidelines are current as of 2024–2025, from authoritative bodies like South African National Department of Health and international expert panels.
• If you have access to internal documents labeled “Neftaly Guidelines,” feel free to share key points or sections you’d like help clarifying or comparing.
• Otherwise, the summary above captures the evidence-based global and South African standard of care for managing HIV in pregnant women.

Let me know if you’d like details on specific ART regimens, infant prophylaxis schedules, breastfeeding support, or local implementation tools!

ChatGPT can make mistakes. Check important info. See Cookie Preferences.

Original text

Rate this translation

Your feedback will be used to help improve Google Translate